Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Vemurafenib
Drug ID BADD_D02344
Description Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E.[A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF.[A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. [L1012]
Indications and Usage Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E.[A31270] The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.[A31271] Vemurafenib approval was extended in 2017, for its use as a treatment of adult patients with Erdheim-Chester Disease whose cancer cells present BRAF V600 mutation.[L1013] Erdheim-Chester disease is an extremely rare histiocyte cell disorder that affects large bones, large vessels, central nervous system, as well as, skin and lungs. It is reported an association of Erdheim-Chester disease and V600E mutation.[A31272]
Marketing Status approved
ATC Code L01EC01
DrugBank ID DB08881
KEGG ID D09996
MeSH ID D000077484
PubChem ID 42611257
TTD Drug ID D0Y9EW
NDC Product Code 50242-090
UNII 207SMY3FQT
Synonyms Vemurafenib | PLX4032 | PLX 4032 | RG7204 | RG-7204 | RG 7204 | Zelboraf | R05185426
Chemical Information
Molecular Formula C23H18ClF2N3O3S
CAS Registry Number 918504-65-1
SMILES CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nausea07.01.07.001--
Neoplasm16.16.02.0010.001824%Not Available
Neoplasm malignant16.16.01.0010.000951%Not Available
Neoplasm skin23.08.02.003; 16.03.02.0030.000392%Not Available
Nephropathy toxic20.05.03.002; 12.03.01.0100.000470%Not Available
Nervous system disorder17.02.10.0010.000392%Not Available
Neuralgia17.02.07.0050.000302%
Neuroendocrine carcinoma of the skin05.08.01.009; 23.08.02.008; 16.03.02.0080.000112%Not Available
Neuropathy peripheral17.09.03.003--Not Available
Nipple disorder21.05.04.0060.000246%
Nocturia20.02.03.0010.000246%Not Available
Nystagmus17.02.02.006; 06.05.02.0060.000112%
Ocular hyperaemia06.04.05.0040.001399%Not Available
Odynophagia07.01.06.0360.000168%Not Available
Oedema08.01.07.006; 14.05.06.0100.001332%Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.0070.001354%
Oesophagitis07.08.05.0010.000280%
Optic neuritis10.02.01.097; 17.04.05.001; 06.04.08.0020.000112%Not Available
Oropharyngeal squamous cell carcinoma22.08.02.006; 16.19.05.004; 07.21.07.005--Not Available
Osteoarthritis15.01.04.0010.000280%Not Available
Osteosclerosis15.02.04.0120.000112%Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Pain of skin23.03.03.0030.000358%
Palmar erythema23.03.06.0100.000112%Not Available
Palmar-plantar erythrodysaesthesia syndrome23.03.05.009; 17.02.07.0090.002048%
Pancreatitis07.18.01.0010.001198%
Pancreatitis acute07.18.01.0020.000560%Not Available
Panniculitis23.07.02.002; 10.01.03.0240.001612%Not Available
Papilloedema24.03.07.001; 17.07.02.004; 06.09.02.0020.000112%
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 14 Pages